IRIS Accounts Production v25.1.3.33 15167583 Board of Directors 26.9.23 30.9.24 30.9.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh151675832023-09-25151675832024-09-30151675832023-09-262024-09-30151675832023-09-2515167583ns15:EnglandWales2023-09-262024-09-3015167583ns14:PoundSterling2023-09-262024-09-3015167583ns10:Director12023-09-262024-09-3015167583ns10:PrivateLimitedCompanyLtd2023-09-262024-09-3015167583ns10:SmallEntities2023-09-262024-09-3015167583ns10:AuditExempt-NoAccountantsReport2023-09-262024-09-3015167583ns10:SmallCompaniesRegimeForDirectorsReport2023-09-262024-09-3015167583ns10:SmallCompaniesRegimeForAccounts2023-09-262024-09-3015167583ns10:FullAccounts2023-09-262024-09-301516758312023-09-262024-09-3015167583ns10:Director22023-09-262024-09-3015167583ns10:RegisteredOffice2023-09-262024-09-3015167583ns5:CurrentFinancialInstruments2024-09-3015167583ns5:Non-currentFinancialInstruments2024-09-3015167583ns5:ShareCapital2024-09-3015167583ns5:RetainedEarningsAccumulatedLosses2024-09-3015167583ns5:NetGoodwill2023-09-262024-09-3015167583ns5:PlantMachinery2023-09-262024-09-3015167583ns5:NetGoodwill2024-09-3015167583ns5:PlantMachinery2024-09-3015167583ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-30
REGISTERED NUMBER: 15167583 (England and Wales)















Unaudited Financial Statements

for the Period 26 September 2023 to 30 September 2024

for

Lotus Pharma Limited

Lotus Pharma Limited (Registered number: 15167583)

Contents of the Financial Statements
for the Period 26 September 2023 to 30 September 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Lotus Pharma Limited

Company Information
for the Period 26 September 2023 to 30 September 2024







DIRECTORS: Mrs Rajdip Kaur Purewal
Mr Gurinder Singh Purewal





REGISTERED OFFICE: Office 1
Hatherton Street
Walsall
WS4 2LA





REGISTERED NUMBER: 15167583 (England and Wales)





ACCOUNTANTS: Dhillon Accountants Limited
Chartered Accountants
Office 1
21 Hatherton Street
Walsall
WS4 2LA

Lotus Pharma Limited (Registered number: 15167583)

Balance Sheet
30 September 2024

Notes £   
FIXED ASSETS
Intangible assets 4 357,105
Tangible assets 5 14,122
371,227

CURRENT ASSETS
Stocks 25,000
Debtors 6 113,190
Cash at bank and in hand 208,074
346,264
CREDITORS
Amounts falling due within one year 7 (489,319 )
NET CURRENT LIABILITIES (143,055 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

228,172

CREDITORS
Amounts falling due after more than
one year

8

(255,950

)

PROVISIONS FOR LIABILITIES (3,530 )
NET LIABILITIES (31,308 )

CAPITAL AND RESERVES
Called up share capital 2
Retained earnings (31,310 )
SHAREHOLDERS' FUNDS (31,308 )

Lotus Pharma Limited (Registered number: 15167583)

Balance Sheet - continued
30 September 2024


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 June 2025 and were signed on its behalf by:





Mr Gurinder Singh Purewal - Director


Lotus Pharma Limited (Registered number: 15167583)

Notes to the Financial Statements
for the Period 26 September 2023 to 30 September 2024


1. STATUTORY INFORMATION

Lotus Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2024, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Lotus Pharma Limited (Registered number: 15167583)

Notes to the Financial Statements - continued
for the Period 26 September 2023 to 30 September 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 9 .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
Additions 360,106
At 30 September 2024 360,106
AMORTISATION
Charge for period 3,001
At 30 September 2024 3,001
NET BOOK VALUE
At 30 September 2024 357,105

Lotus Pharma Limited (Registered number: 15167583)

Notes to the Financial Statements - continued
for the Period 26 September 2023 to 30 September 2024


5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 14,619
At 30 September 2024 14,619
DEPRECIATION
Charge for period 497
At 30 September 2024 497
NET BOOK VALUE
At 30 September 2024 14,122

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade debtors 93,888
Other debtors 19,302
113,190

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Bank loans and overdrafts 46,013
Trade creditors 170,890
Taxation and social security 1,591
Other creditors 270,825
489,319

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
£   
Bank loans 255,950

9. ULTIMATE CONTROLLING PARTY

The company's ultimate controlling parties are Mr Gurinder Singh Purewal and Mrs Rajdip Kaur Purewal by virtue of their ownership of 100% of the issued share capital in the company.